title: TZDs and Bone: A Review of the Recent Clinical Evidence.
abstract: Over the past two years, evidence has emerged that the currently available thiazolidinediones (TZDs), rosiglitazone, and pioglitazone have negative skeletal consequences, at least in women, which are clinically important. Increased fracture risk in women, but not men, was reported for both TZDs, based on analyses of adverse event reports from clinical trials. In short-term clinical trials in women, both TZDs caused more rapid bone loss. In these trials, changes in bone turnover markers suggest a pattern of reduced bone formation without a change in resorption. Although limited, these results support the hypothesis based on rodent and in vitro models that reduced bone formation resulting from activation of peroxisome proliferator-activated receptor-gamma (PPARgamma) is a central mechanism for TZDs' effect on bone. Research is needed to better understand the mechanisms of bone loss with TZDs, to identify factors that influence susceptibility to TZD-induced osteoporosis, and to test treatments for its prevention.
authors.affiliation: Department of Epidemiology and Biostatistics, University of California San Francisco, 185 Berry Street, Suite 5700, San Francisco, CA 94107, USA.
authors.forename: Ann V
authors.initials: AV
authors.lastname: Schwartz
references.citation: Osteoporos Int. 2002 Oct;13(10):777-87
references.pmid: 12378366
references.citation: Diabetes Care. 2007 Jun;30(6):1574-6
references.pmid: 17363747
references.citation: Osteoporos Int. 2008 Feb;19(2):129-37
references.pmid: 17901911
references.citation: Calcif Tissue Int. 2003 Dec;73(6):515-9
references.pmid: 14517715
references.citation: Endocrinology. 2004 Jan;145(1):401-6
references.pmid: 14500573
references.citation: PPAR Res. 2006;2006:24502
references.pmid: 17259663
references.citation: J Clin Invest. 1998 Oct 15;102(8):1627-33
references.pmid: 9788977
references.citation: J Clin Endocrinol Metab. 2008 May;93(5):1696-701
references.pmid: 18285411
references.citation: Diabetes Care. 2008 May;31(5):845-51
references.pmid: 18223031
references.citation: Bone Miner. 1990 Apr;9(1):71-81
references.pmid: 2337690
references.citation: PPAR Res. 2006;2006:27489
references.pmid: 17259664
references.citation: N Engl J Med. 2006 Dec 7;355(23):2427-43
references.pmid: 17145742
references.citation: Expert Opin Drug Saf. 2008 Jan;7(1):69-78
references.pmid: 18171315
references.citation: J Clin Endocrinol Metab. 2007 Sep;92(9):3523-30
references.pmid: 17595249
references.citation: J Clin Endocrinol Metab. 2006 Sep;91(9):3349-54
references.pmid: 16608888
references.citation: Calcif Tissue Int. 2004 Oct;75(4):329-37
references.pmid: 15549648
references.citation: J Clin Endocrinol Metab. 2007 Apr;92(4):1305-10
references.pmid: 17264176
references.citation: Endocrinology. 2007 Jun;148(6):2669-80
references.pmid: 17332064
references.citation: J Bone Miner Res. 2000 Jun;15(6):1006-13
references.pmid: 10841169